Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biopython: freely available python tools for computational molecular biology and bioinformatics
Cock, P. J. A., Antao, T., Chang, J. T., Chapman, B. A., Cox, C. J., Dalke, A., Friedberg, I., Hamelryck, T., Kauff, F., Wilczynski, B., et al. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp163 · Cited by 6,080
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Raue, A., Kreutz, C., Maiwald, T., Bachmann, J., Schilling, M., Klingmüller, U., & Timmer, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp358 · Cited by 1,442
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Dissecting the genomic complexity underlying medulloblastoma
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature · doi:10.1038/nature11284 · Cited by 839
Self-citationMutational signatures of ionizing radiation in second malignancies
Behjati, S., Gundem, G., Wedge, D. C., Roberts, N. D., Tarpey, P. S., Cooke, S. L., Van Loo, P., Alexandrov, L. B., Ramakrishna, M., Davies, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12605 · Cited by 274
Cited by
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Umbaugh, C. S., Groth, M., Erkut, C., Lee, K.-S., Marinho, J., Linder, S., Iser, F., Kapp, J. N., Schroeter, P., Dolaner, S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2796 · Cited by 6
Self-citation
Metadata
- Authors
- Gröschel, S., Hübschmann, D., Raimondi, F., Horak, P., Warsow, G., Fröhlich, M., Klink, B., Gieldon, L., Hutter, B., Kleinheinz, K., Bonekamp, D., Marschal, O., Chudasama, P., Mika, J., Groth, M., Uhrig, S., Krämer, S., Heining, C., Heilig, C. E., Richter, D., Reisinger, E., Pfütze, K., Eils, R., Wolf, S., von Kalle, C., Brandts, C., Scholl, C., Weichert, W., Richter, S., Bauer, S., Penzel, R., Schröck, E., Stenzinger, A., Schlenk, R. F., Brors, B., Russell, R. B., Glimm, H., Schlesner, M., & Fröhling, S.
- Venue
- Nature Communications
- Published
- 2019-04-09
- Volume
- 10
- Issue
- 1
- Pages
- 1635-1635
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2939212185
- Cited by
- 91
- References
- 8
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. https://app.cochat.ai/papers/10.1038/s41467-019-09633-9
- The paper
- Gröschel, S., Hübschmann, D., Raimondi, F., Horak, P., Warsow, G., Fröhlich, M., Klink, B., Gieldon, L., Hutter, B., Kleinheinz, K., Bonekamp, D., Marschal, O., Chudasama, P., Mika, J., Groth, M., Uhrig, S., Krämer, S., Heining, C., Heilig, C. E., . . . Fröhling, S. (2019). Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications. https://doi.org/10.1038/s41467-019-09633-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.